Skip to content

Study · Non-randomized trial · n = 10 · 2009

1 result

The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.

Roemmler J, Steffin B, Gutt B, Sievers C, Bidlingmaier M, Schopohl J

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society23 Dec 2008Cited by 1 (Europe PMC)

PMID19109045 (opens in a new tab)DOI10.1016/j.ghir.2008.11.002 (opens in a new tab)PepBankPUB-19109045
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In ten acromegaly patients on constant pegvisomant, pegvisomant levels did not differ significantly between the pegvisomant-alone and pegvisomant-plus-octreotide profiles and did not change significantly during the tests.

    In plain wordsIn acromegaly patients on pegvisomant, pegvisomant levels did not differ significantly with or without an added octreotide injection.

    Peptide
    Pegvisomant
    Outcome
    No significant changePegvisomant levels with versus without added octreotide
    Study

    n = 10

    Comparator
    pegvisomant alone profile (P) versus pegvisomant plus 100 microg octreotide sc profile (PO)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant levels did not differ significantly between profiles and did not change significantly during the tests.
    2 context sentences
    Summary · context
    Ten acromegalic patients on constant pegvisomant therapy were included.
    Summary · context
    Two 6-h GH secretion profiles were performed once after pegvisomant alone (P), the other after an additional 100 microg octreotide sc injection (PO).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.